About Illingworth research group limited
Illingworth Research Group Limited: Revolutionizing Clinical Research Services
Illingworth Research Group Limited is a leading clinical research organization that provides innovative and patient-centric solutions to the pharmaceutical, biotechnology, and medical device industries. The company was founded in 1998 by John Illingworth, a renowned clinical researcher with over 30 years of experience in the field.
With its headquarters in Manchester, UK, Illingworth Research Group has established itself as a global leader in clinical research services. The company's mission is to make clinical research easier for patients while ensuring that pharmaceutical companies get accurate and reliable data to develop new drugs and therapies.
The team at Illingworth Research Group comprises highly skilled professionals who are passionate about their work. They have extensive experience in all aspects of clinical research, including project management, site monitoring, data management, regulatory affairs, medical writing, and quality assurance.
One of the key strengths of Illingworth Research Group is its patient-centric approach to clinical trials. The company understands that patients are at the heart of every trial and therefore strives to make their participation as comfortable as possible. To achieve this goal, Illingworth has developed innovative solutions such as mobile research units (MRUs) that bring the trial directly to the patient's home or workplace.
The MRUs are fully equipped with state-of-the-art equipment for conducting various tests such as blood draws and ECGs. This eliminates the need for patients to travel long distances or spend time waiting at clinics or hospitals. It also ensures that patients can participate in trials regardless of their location or mobility issues.
Another unique feature of Illingworth's services is its focus on rare disease trials. The company recognizes that these trials pose unique challenges due to small patient populations scattered across different regions or countries. To overcome these challenges, Illingworth has developed specialized expertise in rare disease trials through partnerships with patient advocacy groups and other stakeholders.
Illingworth's commitment to quality is reflected in its ISO 9001:2015 certification for quality management systems (QMS). This certification demonstrates the company's dedication to continuous improvement and customer satisfaction through effective QMS implementation.
In addition to its core services such as site monitoring and project management, Illingworth offers a range of complementary services such as medical writing and regulatory affairs consulting. These services help clients navigate complex regulatory requirements while ensuring compliance with international standards such as Good Clinical Practice (GCP).
Overall, Illingworth Research Group Limited stands out from other CROs due to its innovative solutions tailored towards making clinical research easier for patients while providing high-quality data for drug development companies. With over two decades of experience serving clients worldwide across various therapeutic areas including oncology neurology cardiology respiratory diseases infectious diseases among others; it continues revolutionizing how we conduct our studies today!